Crohn's Disease Clinical Trials

99 recruitingLast updated: June 17, 2026

There are 99 actively recruiting crohn's disease clinical trials across 60 countries. Studies span Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4, Early Phase 1. Top locations include New York, New York, United States, Milan, Italy, Warsaw, Poland. Updated daily from ClinicalTrials.gov.


Crohn's Disease Trials at a Glance

99 actively recruiting trials for crohn's disease are listed on ClinicalTrialsFinder across 6 cities in 60 countries. The largest study group is Phase 3 with 19 trials, with the heaviest enrollment activity in New York, Milan, and Warsaw. Lead sponsors running crohn's disease studies include Takeda, AbbVie, and Sanofi.

Browse crohn's disease trials by phase

Treatments under study

About Crohn's Disease Clinical Trials

Looking for clinical trials for Crohn's Disease? There are currently 87 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Crohn's Disease trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Crohn's Disease clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 99 trials

Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled499 locationsNCT06430801
Recruiting
Phase 3

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Crohn's DiseaseUlcerative Colitis
Takeda70 enrolled1 locationNCT06405087
Recruiting
Phase 2

A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.

Crohn's Disease
Sanofi260 enrolled139 locationsNCT06637631
Recruiting
Phase 4

A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting

Crohn's DiseaseUlcerative Colitis
Takeda400 enrolled100 locationsNCT06581328
Recruiting
Not Applicable

Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease

Crohn's Disease
Cairo University50 enrolled1 locationNCT07531342
Recruiting

A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag G.m.b.H500 enrolled1 locationNCT07102368
Recruiting
Phase 3

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease
Janssen Research & Development, LLC120 enrolled85 locationsNCT05923073
Recruiting

A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Crohn's Disease in the United Kingdom (UK)

Crohn's DiseaseInflammatory Bowel DiseaseColitis Ulcerative
Janssen-Cilag Ltd.220 enrolled1 locationNCT07242248
Recruiting
Phase 2

Amitriptyline for IBS-like Symptoms in Quiescent Crohn's Disease

Quiescent Crohn's Disease (CD)
University of Michigan100 enrolled1 locationNCT07556718
Recruiting
Phase 2

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

Crohn's Disease
AbbVie540 enrolled255 locationsNCT06548542
Recruiting
Phase 2

A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

Inflammatory Bowel DiseasesCrohn's Disease
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)385 enrolled226 locationsNCT06226883
Recruiting
Phase 3

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative Colitis+1 more
Eli Lilly and Company150 enrolled67 locationsNCT04844606
Recruiting
Phase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 1

A Phase I Study to Evaluate the Safety/Tolerability of BDHK-2009 Tablets in Healthy Adult

IBD (Inflammatory Bowel Disease)Ulcerative Colitis (UC)CD - Crohn's Disease+2 more
Benethera (Shaoxing) Biotechnology Co., Ltd.68 enrolled1 locationNCT07632573
Recruiting
Phase 3

Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Crohn's Disease
AbbVie110 enrolled85 locationsNCT06332534
Recruiting
Phase 3

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease
Sanofi980 enrolled259 locationsNCT07184931
Recruiting
Phase 3

A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease

Crohn's Disease
AbbVie110 enrolled85 locationsNCT05995353
Recruiting
Phase 3

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Crohn's Disease
Takeda396 enrolled138 locationsNCT06227910
Recruiting
Phase 3

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Crohn's Disease
Eli Lilly and Company90 enrolled81 locationsNCT05509777
Recruiting

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

Ulcerative Colitis (UC)Inflammatory Bowel Disease (IBD)Indeterminate Colitis+1 more
University of North Carolina, Chapel Hill200 enrolled9 locationsNCT07237516